Slideshows Images Quizzes

Prialt

Last reviewed on RxList: 4/5/2016
Prialt Side Effects Center

Last reviewed on RxList 1/10/2016

Prialt (ziconotide) is a non-narcotic pain reliever used to treat severe chronic pain in people who cannot use or do not respond to standard pain-relieving medications. Common side effects of Prialt include dizziness, spinning sensation, drowsiness, nausea, headache, weakness, joint pain, sleep problems, unusual dreams, stomach pain, diarrhea, constipation, loss of appetite, urinating less than usual, or loss of balance or coordination.

The dose of Prialt is determined by a physician and it is administered in a clinical setting. Prialt may interact with other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety), or diuretics (water pills). Tell your doctor all medications you use. Prialt should be used only when prescribed during pregnancy. It is unknown if this medication passes into breast milk, and it is unlikely to harm a nursing infant. Consult your doctor before breastfeeding.

Our Prialt (ziconotide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Prialt Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • problems with memory, speech, walking, or thinking;
  • feeling like you might pass out;
  • double vision or other vision problems;
  • new or worsening muscle pain, cramps, soreness, or weakness, and/or dark urine;
  • unusual bleeding or signs of infection around the microinfusion entry or catheter exit sites;
  • fever, headache, neck stiffness, chills, increased sensitivity to light, purple spots on the skin, nausea, vomiting, and/or seizure (convulsions);
  • extreme drowsiness or tired feeling, depressed mood;
  • feeling paranoid, hostile, disoriented, or confused;
  • strange sensations in your mouth;
  • hallucinations, unusual thoughts or behavior, thoughts of hurting yourself; or
  • feeling less alert, decreased consciousness (stupor or lack of response).

Less serious side effects may include:

  • headache, joint pain;
  • mild drowsiness or weakness;
  • dizziness, spinning sensation;
  • sleep problems, unusual dreams;
  • stomach pain, diarrhea, constipation, loss of appetite;
  • urinating less than usual; or
  • loss of balance or coordination.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Prialt (Ziconotide)

Prialt Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates in clinical practice.

A total of 1254 adult patients received PRIALT as a continuous infusion in acute and severe chronic pain trials with an exposure of 662 patient-years. The mean duration of treatment was 193 days with 173 patients (14%) treated for at least 1 year. The average final dose was 17.6 mcg/day (0.73 mcg/hr).

The most frequently reported adverse reactions ( ≥ 25%) in clinical trials were dizziness, nausea, confusional state and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuation of PRIALT for adverse reactions [see Clinical Studies and DOSAGE AND ADMINISTRATION].

Adverse reactions during the slow titration placebo-controlled trial that occurred in 5% or greater of patients and more commonly with PRIALT than with placebo are summarized in Table 1.

Table 1: Incidence of Adverse Reactions in Slow Titration Placebo-Controlled Trial by Percent (Events That Occurred in ≥ 5% of Patients and More Commonly with PRIALT than with Placebo)

MedDRA System Organ Class
MedDRA Preferred term
PRIALT
N=112
Placebo
N=108
Percentage of Patients
Any AE 93 82
Ear and Labyrinth Disorders
  Vertigo 7 0
Eye Disorders
  Vision Blurred 12 3
Gastrointestinal Disorders
  Diarrhea 18 15
  Nausea 40 29
  Vomiting 16 14
General Disorders and Administration Site Conditions
  Asthenia 18 6
  Gait Abnormal 14 2
  Pyrexia 5 3
  Rigors 7 5
Infections and Infestations
  Sinusitis 5 2
Metabolism and Nutrition Disorders
  Anorexia 6 2
Musculoskeletal and Connective Tissue Disorders
  Muscle Spasms 6 4
  Pain in Limb 5 2
Nervous System Disorders
  Amnesia 8 0
  Ataxia 14 1
  Dizziness 46 13
  Dysarthria 7 0
  Dysgeusia 5 5
  Headache 13 11
  Memory Impairment 7 1
  Nystagmus 8 0
  Somnolence 17 10
  Tremor 7 3
Psychiatric Disorders
  Anxiety 8 3
  Confusional State 15 5
  Insomnia 6 9
Renal and Urinary Disorders
  Urinary Retention 9 0
Skin and Subcutaneous Disorders
  Pruritis 7 7
  Sweating Increased 5 6

Other Adverse Reactions Observed During Clinical Studies Of PRIALT

The following adverse reactions assessed as related to PRIALT have been reported in 2% or greater of patients participating in the clinical studies:

EYE DISORDERS: diplopia, visual disturbance

GASTROINTESTINAL DISORDERS: abdominal pain, constipation, dry mouth, nausea aggravated

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: fall, fatigue, lethargy, edema peripheral

INVESTIGATIONS: blood creatine phosphokinase increased

METABOLISM AND NUTRITION DISORDERS: appetite decreased

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: muscle cramp, muscle weakness, myalgia, pain in limb

NERVOUS SYSTEM DISORDERS: aphasia, areflexia, balance impaired, burning sensation, coordination abnormal, disturbance in attention, dizziness postural, dysarthria, dysgeusia, hypoaesthesia, mental impairment, paraesthesia, sedation, speech disorder

PSYCHIATRIC DISORDERS: agitation, anxiety, cognitive disorder, confusional state, depression, depression aggravated, disorientation, hallucination, hallucination auditory, hallucination visual, insomnia, irritability, mood disorder, nervousness, paranoia

RENAL AND URINARY DISORDERS: dysuria, urinary hesitation

VASCULAR DISORDERS: hypotension, orthostatic hypotension.

The following medically important adverse reactions occurred in less than 2% of patients were assessed by the clinical investigators as related to PRIALT: acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, electrocardiogram abnormal, stupor, loss of consciousness, clonic convulsion and grand mal convulsion. Fatal aspiration pneumonia and suicide attempt were reported in less than 1% of patients.

Postmarketing Experience

The following adverse events have been reported during post-approval use of PRIALT. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Hypersensitivity reactions including angioedema, serious skin reactions including bullous dermatitis, skin ulcers, skin exfoliation, and burning skin sensation.

Read the entire FDA prescribing information for Prialt (Ziconotide)

Related Resources for Prialt

Read the Prialt User Reviews »

© Prialt Patient Information is supplied by Cerner Multum, Inc. and Prialt Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors